Patents by Inventor John Michael Morin

John Michael Morin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
    Patent number: 7229987
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I); or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.
    Type: Grant
    Filed: May 6, 2003
    Date of Patent: June 12, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jochen Ammenn, James Ronald Gillig, Lawrence Joseph Heinz, Philip Arthur Hipskind, Michael Dean Kinnick, Yen-Shi Lai, John Michael Morin, Jr., James Arthur Nixon, Carsten Ott, Kenneth Allen Savin, Theo Schotten, Lawrence John Slieker, Nancy June Snyder, Michael Alan Robertson
  • Cyclopenta[b]indole derivatives as sPLAinhibitors
    Patent number: 7160909
    Abstract: A novel class of tricyclic compounds of the following formula (I) is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: January 9, 2007
    Assignee: Eli Lilly and Company
    Inventors: Michael Dean Kinnick, Edward David Mihelich, John Michael Morin, Daniel Jon Sall, Jason Scott Sawyer
  • MCH receptor antagonists
    Patent number: 7132456
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of Formula I: (I) wherein Ar1, Ar2, Ar3, L1, L2 and Q areas defined, or a pharmaceutically acceptable salt, solvate, enantiomer or mixture of diastereomers thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and Related Diseases
    Type: Grant
    Filed: December 3, 2003
    Date of Patent: November 7, 2006
    Assignee: Eli Lilly and Company
    Inventors: James Ronald Gillig, Lawrence Joseph Heinz, Michael Dean Kinnick, Yen-Shi Lai, John Michael Morin, Nancy June Snyder
  • Cyclohept[b]indole derivatives
    Patent number: 7109231
    Abstract: A novel class of tricyclic compounds of the following formula (I): (formula I); is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of inflammatory diseases such as septic shock
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: September 19, 2006
    Assignee: Eli Lilly and Company
    Inventors: Michael Dean Kinnick, Edward David Mihelich, John Michael Morin, Jr., Daniel Jon Sall, Jason Scott Sawyer
  • sPLAinhibitors
    Patent number: 6992100
    Abstract: A novel class of tetracyclic compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: January 31, 2006
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Jr., Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, John David Jandzinski
  • sPLA2 inhibitors
    Patent number: 6974831
    Abstract: A novel class of cycloalkyl fused indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: December 13, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • sPLA2 inhibitors
    Patent number: 6930123
    Abstract: A novel class of benz[f]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: August 16, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Spla2 inhibitors
    Patent number: 6916840
    Abstract: A novel class of benz[g]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: July 12, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Jr., Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • sPLA2 inhibitors
    Patent number: 6872743
    Abstract: A novel class of tetracyclic compounds represented by the formula I wherein R1, R2, R3, R4, R5, R6, R7, A, B, C, D, E, and n are as defined is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: March 29, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Jr., Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer
  • Cyclohept'b!indole derivatives as spla2 inhibitors
    Publication number: 20040198801
    Abstract: 1
    Type: Application
    Filed: January 15, 2004
    Publication date: October 7, 2004
    Inventors: Michael Dean Kinnick, Edward David Mihelich, John Michael Morin, Daniel Jon Sall, Jason Scott Sawyer
  • Compounds and methods for inhibition of HIV and related viruses
    Publication number: 20040116418
    Abstract: The present invention is directed to compounds, compositions and methods of inhibiting and treating HIV and related viruses, and methods for cocrystallizing reverse transcriptase in vitro, inhibition of the replication of HIV and related viruses thereof.
    Type: Application
    Filed: December 1, 2003
    Publication date: June 17, 2004
    Applicant: Medivir AB
    Inventors: Peter Thomas Lind, Rolf Noreen, John Michael Morin, Robert John Ternansky
  • Novel spla2 inhibitors
    Publication number: 20040092543
    Abstract: A novel class of tetracyclic compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: June 16, 2003
    Publication date: May 13, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin Jr, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, John David Jandzinski
  • sPLA2 inhibitors
    Patent number: 6730694
    Abstract: A class of novel substituted pyrrole is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: May 4, 2004
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, John Michael Morin, Jr., Jason Scott Sawyer, Edward C R Smith
  • Novel spla2 inhibitors
    Publication number: 20040077704
    Abstract: A novel class of cycloalkyl fused indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: June 16, 2003
    Publication date: April 22, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Novel spla2 inhibitors
    Publication number: 20040063967
    Abstract: A novel class of benz[g]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: June 16, 2003
    Publication date: April 1, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Novel spla2 inhibitors
    Publication number: 20040063941
    Abstract: A novel class of tetracyclic compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock
    Type: Application
    Filed: June 16, 2003
    Publication date: April 1, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer
  • Substituted tricyclics
    Patent number: 6713645
    Abstract: A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: March 30, 2004
    Assignee: Eli Lilly and Company
    Inventors: Nicholas James Bach, Susan Elizabeth Draheim, Robert Delane Dillard, Edward David Mihelich, Jason Scott Sawyer, Douglas Wade Beight, Michael LeRoy Phillips, Tulio Suarez, Daniel Jon Sall, Jolie Anne Bastian, Michael Lyle Denney, Gary Alan Hite, Michael Dean Kinnick, Robert Theodore Vasileff, John Michael Morin, Jr., Ho-Shen Lin, Michael Enrico Richett, Richard Waltz Harper, John McNeill McGill, III, Benjamin Alan Anderson, Nancy Kay Harn, Richard James Loncharich, Richard Walter Schevitz
  • spla2 inhibitors
    Patent number: 6713505
    Abstract: A class of novel benzo(b)thiophene is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: March 30, 2004
    Assignee: Eli Lilly and Company
    Inventors: Michael Dean Kinnick, Ho-Shen Lin, Michael John Martinelli, John Michael Morin, Michael Enrico Richett
  • Spla2 inhibitors
    Publication number: 20040059130
    Abstract: A novel class of benz[f]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: June 16, 2003
    Publication date: March 25, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Novel spla2 inhibitors
    Publication number: 20030236232
    Abstract: A class of novel benzo(b)thiophene is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: December 3, 2002
    Publication date: December 25, 2003
    Inventors: Michael Dean Kinnick, Ho-Shen Lin, Michael John Martinelli, John Michael Morin, Michael Enrico Richett